Literature DB >> 14967736

Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.

Yoko Irukayama-Tomobe1, Takashi Miyauchi, Satoshi Sakai, Yoshitoshi Kasuya, Takehiro Ogata, Masakatsu Takanashi, Motoyuki Iemitsu, Tatsuhiko Sudo, Katsutoshi Goto, Iwao Yamaguchi.   

Abstract

BACKGROUND: Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is a lipid-activated nuclear receptor that negatively regulates the vascular inflammatory gene response by interacting with transcription factors, nuclear factor-kappaB, and AP-1. However, the roles of PPAR-alpha activators in endothelin (ET)-1-induced cardiac hypertrophy are not yet known. METHODS AND
RESULTS: First, in cultured neonatal rat cardiomyocytes, a PPAR-alpha activator, fenofibrate (10 micromol/L), and PPAR-alpha overexpression markedly inhibited the ET-1-induced increase in protein synthesis. Second, fenofibrate markedly inhibited ET-1-induced increase in c-Jun gene expression and phosphorylation of c-Jun and JNK. These results suggest that this PPAR-alpha activator interferes with the formation and activation of AP-1 protein induced by ET-1 in cardiomyocytes. Third, fenofibrate significantly inhibited the increase of ET-1 mRNA level by ET-1, which was also confirmed by luciferase assay. Electrophoretic mobility shift assay revealed that fenofibrate significantly decreased the ET-1-stimulated or phorbol 12-myristate 13-acetate-stimulated AP-1 DNA binding activity, and the nuclear extract probe complex was supershifted by anti-c-Jun antibody. Fourth, 24 hours after aortic banding (AB) operation, fenofibrate treatment significantly inhibited left ventricular hypertrophy and hypertrophy-related gene expression pattern (ET-1, brain natriuretic peptide, and beta-myosin heavy chain mRNA) in AB rats.
CONCLUSIONS: These results suggest that PPAR-alpha activation interferes with the signaling pathway of ET-1-induced cardiac hypertrophy through negative regulation of AP-1 binding activity, partly via inhibition of the JNK pathway in cultured cardiomyocytes. We also revealed that fenofibrate treatment inhibited left ventricle hypertrophy and phenotypic changes in cardiac gene expression in AB rats in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967736     DOI: 10.1161/01.CIR.0000112596.06954.00

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.

Authors:  Raquel Grau; Carmen Punzón; Manuel Fresno; Miguel A Iñiguez
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 3.  Endothelin-1 and its role in the pathogenesis of infectious diseases.

Authors:  Brandi D Freeman; Fabiana S Machado; Herbert B Tanowitz; Mahalia S Desruisseaux
Journal:  Life Sci       Date:  2014-04-26       Impact factor: 5.037

4.  PPARα-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway.

Authors:  Shinichi Oka; Ralph Alcendor; Peiyong Zhai; Ji Yeon Park; Dan Shao; Jaeyeaon Cho; Takanobu Yamamoto; Bin Tian; Junichi Sadoshima
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287

Review 5.  The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation.

Authors:  Kristine M Wadosky; Monte S Willis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-28       Impact factor: 4.733

Review 6.  Peroxisome proliferator-activated receptor alpha and hypertensive heart disease.

Authors:  Maria J Goikoetxea; Javier Beaumont; Javier Díez
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4.

Authors:  Kang Le; Ruifang Li; Suowen Xu; Xiaoqian Wu; Heqing Huang; Yingxia Bao; Yi Cai; Tian Lan; Joel Moss; Cuixian Li; Jian Zou; Xiaoyan Shen; Peiqing Liu
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

8.  Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease.

Authors:  Herbert B Tanowitz; Huan Huang; Linda A Jelicks; Madhulika Chandra; Maria L Loredo; Louis M Weiss; Stephen M Factor; Vitaliy Shtutin; Shankar Mukherjee; Richard N Kitsis; George J Christ; Murray Wittner; Jamshid Shirani; Yaz Y Kisanuki; Masashi Yanagisawa
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

9.  Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta.

Authors:  Pascal J H Smeets; Birgit E J Teunissen; Anna Planavila; Heleen de Vogel-van den Bosch; Peter H M Willemsen; Ger J van der Vusse; Marc van Bilsen
Journal:  J Biol Chem       Date:  2008-08-12       Impact factor: 5.157

10.  Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms.

Authors:  Deepa S De Silva; Richard M Wilson; Christoph Hutchinson; Peter C Ip; Anthony G Garcia; Steve Lancel; Masa Ito; David R Pimentel; Flora Sam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.